Reaction Biology Corporation ("RBC") has announced that it has received the highest number of positive ratings in a recent industry survey.
HTStec, a UK-based technical research firm, surveyed 78 research labs around the globe for its Kinase Profiling Trends 2013 report. The labs included large pharmas, biotechs, university and non-profit labs.
Survey participants were asked to rate the 16 top kinase profiling outsource providers on eight different attributes.
The provider with the highest number of positive ratings was RBC, which came in number one on customer service, turnaround time, and low cost.
RBC also ranked as the most-used provider to the industry, rising from fifth place in the same survey taken in 2010.
“We are very pleased with this validation of our efforts to provide the widest coverage of the kinome, with a gold standard activity assay,” said Dr. Haiching Ma, Chief Science Officer of RBC.
Dr. Ma continued, “Eighty-eight percent of all pharmas in the survey preferred activity-based assays, and RBC’s radiolabeled HotSpot assay now provides high-quality reproducible data on 457 kinases.”
The survey estimated that RBC had the largest share of the $34 million kinase profiling market.
Based in Malvern, PA, RBC is a premier provider of drug screening and profiling services. With more than 450 kinases, RBC’s coverage of the kinome is the broadest in the industry.
Using its proprietary HotSpotSM technology and other innovations, RBC is expanding its already substantial production of epigenetic regulatory enzymes.
RBC has provided its services to over 300 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.